Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market

After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.

Stressed Woman with Headache on the Beach. Outdoor Sad Woman
Vyepti is now approved in the US for migraine prevention • Source: Shutterstock

Lundbeck Inc. does not see the intravenous administration of its newly approved migraine prevention therapy Vyepti (eptinezumab-jjmr) as a hurdle to commercial success despite the availability of three subcutaneously administered calcitonin gene-related peptide (CGRP) inhibitors in the US. Instead, the company believes that being the only anti-CGRP drug administered by I.V. infusion Vyepti makes an attractive migraine prevention option to replace older, less effective medicines.

However, the company is also coming in at a lower price than the other CGRP drugs, which have been on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip